[go: up one dir, main page]

MX2018001491A - Metodos para la preparacion de acidos biliares y derivados de los mismos. - Google Patents

Metodos para la preparacion de acidos biliares y derivados de los mismos.

Info

Publication number
MX2018001491A
MX2018001491A MX2018001491A MX2018001491A MX2018001491A MX 2018001491 A MX2018001491 A MX 2018001491A MX 2018001491 A MX2018001491 A MX 2018001491A MX 2018001491 A MX2018001491 A MX 2018001491A MX 2018001491 A MX2018001491 A MX 2018001491A
Authority
MX
Mexico
Prior art keywords
derivatives
preparation
methods
bile acids
solvate
Prior art date
Application number
MX2018001491A
Other languages
English (en)
Inventor
M Galvin Gabriel
Original Assignee
Intercept Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intercept Pharmaceuticals Inc filed Critical Intercept Pharmaceuticals Inc
Publication of MX2018001491A publication Critical patent/MX2018001491A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente solicitud se refiere a un método de preparación de compuestos de fórmula (A): (ver formula) O una sal, solvato o conjugado con aminoácidos farmacéuticamente aceptable del mismo.
MX2018001491A 2015-08-07 2016-08-05 Metodos para la preparacion de acidos biliares y derivados de los mismos. MX2018001491A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562202300P 2015-08-07 2015-08-07
PCT/US2016/045831 WO2017027396A1 (en) 2015-08-07 2016-08-05 Methods for preparation of bile acids and derivatives thereof

Publications (1)

Publication Number Publication Date
MX2018001491A true MX2018001491A (es) 2018-04-24

Family

ID=57983768

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018001491A MX2018001491A (es) 2015-08-07 2016-08-05 Metodos para la preparacion de acidos biliares y derivados de los mismos.

Country Status (14)

Country Link
US (1) US10604544B2 (es)
EP (1) EP3331896A4 (es)
JP (1) JP2018522054A (es)
KR (1) KR20180028544A (es)
CN (1) CN108137643A (es)
AR (1) AR105648A1 (es)
AU (1) AU2016306297A1 (es)
BR (1) BR112018002499A2 (es)
CA (1) CA2994687A1 (es)
HK (1) HK1252688A1 (es)
IL (1) IL257235A (es)
MX (1) MX2018001491A (es)
TW (1) TW201714891A (es)
WO (1) WO2017027396A1 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2966885A1 (en) 2014-11-06 2016-05-12 Enanta Pharmaceuticals, Inc. Bile acid analogs an fxr/tgr5 agonists and methods of use thereof
WO2016086115A1 (en) 2014-11-26 2016-06-02 Enanta Pharmaceuticals, Inc. Tetrazole derivatives of bile acids as fxr/tgr5 agonists and methods of use thereof
US10208081B2 (en) 2014-11-26 2019-02-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
HK1244708A1 (zh) 2014-11-26 2018-08-17 英安塔制药有限公司 作爲fxr/tgr5激动剂的胆汁酸类似物及其使用方法
RU2017130466A (ru) 2015-02-11 2019-03-12 Энанта Фармасьютикалс, Инк. Аналоги желчной кислоты в качестве агонистов fxr/tgr5 и способы их применения
NZ735126A (en) 2015-03-31 2022-10-28 Enanta Pharm Inc Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
KR20180052756A (ko) * 2015-09-24 2018-05-18 인터셉트 파마슈티컬즈, 인크. 담즙산 유도체 제조를 위한 방법 및 중간체
US10323060B2 (en) 2016-02-23 2019-06-18 Enanta Pharmaceuticals, Inc. Benzoic acid derivatives of bile acid as FXR/TGR5 agonists and methods of use thereof
WO2017147159A1 (en) 2016-02-23 2017-08-31 Enanta Pharmaceuticals, Inc. Deuterated bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
US10323061B2 (en) 2016-02-23 2019-06-18 Enanta Pharmaceuticals, Inc. Heteroaryl containing bile acid analogs as FXR/TGR5 agonists and methods of use thereof
ES2874682T3 (es) 2016-03-11 2021-11-05 Intercept Pharmaceuticals Inc Derivados de 3-desoxi y composiciones farmacéuticas de los mismos
WO2018064441A1 (en) * 2016-09-30 2018-04-05 Intercept Pharmaceuticals, Inc Crystalline forms of a bile acid derivative
EP3305799A3 (en) * 2016-10-07 2018-06-20 Lupin Limited Salts of obeticholic acid
WO2018102418A1 (en) 2016-11-29 2018-06-07 Enanta Pharmaceuticals, Inc. Process for preparation of sulfonylurea bile acid derivatives
US10472386B2 (en) 2017-02-14 2019-11-12 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR agonists and methods of use thereof
CA3058754A1 (en) 2017-04-07 2018-10-11 Enanta Pharmaceuticals, Inc. Process for preparation of sulfonyl carbamate bile acid derivatives
CN107298694A (zh) * 2017-04-21 2017-10-27 华东师范大学 奥贝胆酸的合成方法及其中间体
BR112019027458A2 (pt) 2017-06-23 2020-07-07 Intercept Pharmaceuticals, Inc. métodos e intermediários para a preparação de derivados de ácidos biliares
JP7308811B2 (ja) 2017-07-26 2023-07-14 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド ステロイド系誘導体ｆｘｒアゴニストの製造方法
GB201812382D0 (en) 2018-07-30 2018-09-12 Nzp Uk Ltd Compounds
JP2022552655A (ja) 2019-10-07 2022-12-19 キャリーオペ，インク． Ｇｐｒ１１９アゴニスト
US20240325458A1 (en) * 2020-01-16 2024-10-03 Keio University Composition for producing bile acids
PH12022552277A1 (en) 2020-02-28 2024-03-04 Kallyope Inc Gpr40 agonists
CA3178994A1 (en) 2020-05-19 2021-11-25 Iyassu Sebhat Ampk activators
JP2023531726A (ja) 2020-06-26 2023-07-25 キャリーオペ，インク． Ａｍｐｋアクチベーター
CN112831536B (zh) * 2021-03-02 2022-07-15 江南大学 细胞色素p450单加氧酶在催化石胆酸生产熊去氧胆酸中的应用
CN113528606B (zh) * 2021-07-22 2023-05-05 湖州颐盛生物科技有限公司 一种酶催化制备17β-羟基类固醇的方法
CN115806578B (zh) * 2021-09-15 2024-11-15 成都百泉生物医药科技有限公司 Nor-UDCA中间体、Nor-UDCA及其中间体的制备方法
CN113968891B (zh) * 2021-11-15 2023-04-07 湖南科瑞生物制药股份有限公司 一种植物源7-酮基石胆酸的制备方法
CN114276401A (zh) * 2021-12-27 2022-04-05 中山百灵生物技术股份有限公司 一种24-去甲熊去氧胆酸的合成方法
EP4615461A1 (en) * 2022-11-11 2025-09-17 Intercept Pharmaceuticals, Inc. Crystalline forms of a farnesoid x receptor agonist
CN117510567B (zh) * 2023-10-26 2025-10-28 长沙启晟合研医药科技有限公司 一种制备高纯度阿法沙龙的方法
CN119320419A (zh) * 2024-10-28 2025-01-17 苏州恩泰新材料科技有限公司 一种24-去甲熊去氧胆酸的合成方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2757156A1 (de) * 1977-12-19 1979-06-21 Schering Ag Verfahren zur herstellung von 21-hydroxy-20-methyl-pregnan-derivaten
US4212940A (en) * 1978-12-19 1980-07-15 Schering Aktiengesellschaft Process for the preparation of 21-hydroxy-20-methylpregnane derivatives
US4230625A (en) * 1979-04-12 1980-10-28 Hoffmann-La Roche Inc. Process for chenodeoxycholic acid and intermediates therefore
CA2928178C (en) * 2007-01-19 2019-09-10 Intercept Pharmaceuticals, Inc. Tgr5 modulators and methods of use thereof
US20130261317A1 (en) 2010-09-27 2013-10-03 Kythera Biopharmaceuticals, Inc. Methods for preparing synthetic bile acids and compositions comprising the same
CN105348354A (zh) * 2014-12-03 2016-02-24 四川百利药业有限责任公司 一类鹅去氧胆酸类化合物及其制备方法和用途

Also Published As

Publication number Publication date
WO2017027396A1 (en) 2017-02-16
TW201714891A (zh) 2017-05-01
EP3331896A1 (en) 2018-06-13
AU2016306297A1 (en) 2018-02-22
BR112018002499A2 (pt) 2018-09-18
KR20180028544A (ko) 2018-03-16
US10604544B2 (en) 2020-03-31
CA2994687A1 (en) 2017-02-16
US20180222937A1 (en) 2018-08-09
AR105648A1 (es) 2017-10-25
JP2018522054A (ja) 2018-08-09
HK1252688A1 (zh) 2019-05-31
IL257235A (en) 2018-03-29
EP3331896A4 (en) 2019-08-14
CN108137643A (zh) 2018-06-08

Similar Documents

Publication Publication Date Title
MX2018001491A (es) Metodos para la preparacion de acidos biliares y derivados de los mismos.
MA43066A (fr) Procédés de préparation d'acides biliaires et de leurs dérivés
MX2018005520A (es) Metodos para preparacion de acido obeticolico y derivados de los mismos.
PH12018500777A1 (en) Farnesoid x receptor modulators
PH12019501688A1 (en) Pyridine derivative as ask1 inhibitor and preparation method and use thereof
EA201592055A1 (ru) 11-гидроксилпроизводные желчных кислот и их аминокислотные конъюгаты в качестве модуляторов фарнезоидных х-рецепторов
MX361653B (es) Procedimiento para la preparación de derivados del ácido biliar.
EA032972B1 (ru) Гетероциклические карбоновые кислоты в качестве активаторов растворимой гуанилатциклазы
EA033544B1 (ru) Производные пиридона в качестве ингибиторов киназы, реаранжированной во время трансфекции (ret)
EP4582424A3 (en) 1,2-naphthoquinone derivative and method for preparing same
MX2019011844A (es) Proceso para la preparación de derivados de ácidos biliares de sulfonil carbamato.
PH12016501461A1 (en) 5-biphenyl-4-heteroarylcarbonylamino-pentanoic acid derivatives as neprilysin inhibitors
SA520411635B1 (ar) A2a مشتق حلقي مدمج كمثبط مستقبل
MY191352A (en) Aldosterone synthase inhibitors
TN2018000188A1 (en) Isoindole compounds
WO2015068175A3 (en) An improved process for the preparation of pazopanib or a pharmaceutically acceptable salt thereof
CA2922375C (en) Alpha-tea salt forms: compositions and uses for treating disease
MX385672B (es) Metodos para preparar 5,6-dihidro-6-fenilbenzo[f]isoquinolin-2-amina sustituida.
MX374550B (es) Métodos para preparación de ácido obeticólico y derivados de los mismos.
MX2018015990A (es) Compuestos terapeuticos.
IL277066A (en) History of LNA-dicarboxylic acid and process for their preparation
PH12019550212B1 (en) Process for the preparation of pirlindole enantiomers and its salts
WO2016027211A3 (en) Process for the preparation of cinacalcet and its pharmaceutically acceptable salts
HK1231073A1 (en) 5-biphenyl-4-heteroarylcarbonylamino-pentanoic acid derivatives as neprilysin inhibitors